PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Latest Additions

Latest Additions

Records returned : 195 (on 03 Jul 2024 at 02:22:17).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
01.03.05
Lansoprazole
Acid suppression (Adults)
Green
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Preferred
1st line for patients with no swallowing difficulties. 2nd line for adults with swallowing difficulties / feeding tubes - capsules can be opened. Click on drug name for details
01.03.05
Omeprazole
Acid suppression (Adults)
Green
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Preferred
1st line for patients with no swallowing difficulties.
01.03.05
Acid Suppression (Children)
Green
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Preferred
1st line option in children who are able to swallow capsules. Most capsules can also be opened and mixed with water or fruit juice (licensed).
03.04.03
Adrenaline
Anaphylaxis
Green
Formulations :
  • Auto-injector
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Prescribe by brand. Injection technique is device-specific
07.04.02
Tamsulosin hydrochloride
Benign prostatic hyperplasia
Green
Formulations :
  • Modified release capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Preferred
06.01.02
Dapagliflozin
Chronic Kidney Disease
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist team may be prudent prior to dapagliflozin initiation.
05.01.07
Fidaxomicin
Clostridioides difficile
Green
Formulations :
  • Oral suspension
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Granules (for oral suspension) should be used in patients requiring a liquid preparation.
07.04.01
Doxazosin
Benign prostatic hyperplasia
Green
Formulations :
  • Immediate release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Preferred
06.01.01
Insulin glargine
Diabetes Mellitus
Green
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Nutilis Clear
Dysphagia
Green
Formulations :
  • Powder
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Resource ThickenUp Clear
Dysphagia
Green
Formulations :
  • Powder
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
06.04.02
Testosterone
Low sexual desire in menopausal women
Green
Formulations :
  • Gel
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
Important
Prescribe generically as "Testosterone 2% transdermal gel 60g"
04.07.04
Candesartan cilexetil
Migraine (prevention)
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
Important
Off-label use
04.07.03
04.07.04
Amitriptyline hydrochloride
Migraine (prevention)
Green
Formulations :
  • Oral solution
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
04.07.04
Propranolol hydrochloride
Migraine (prevention)
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
04.07.04
04.08.01
Topiramate
Migraine (prevention)
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
SA
Important
Pregnancy Prevention Plan required for females of childbearing potential.
04.06.00
Domperidone
Nausea and vomiting (Parkinson's disease)
Green
Formulations :
  • Oral suspension
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
SA
Un
10.03.02
Capsaicin
Osteoarthritis
Green
Formulations :
  • Cream
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
0.025% cream (Zacin brand) is licensed for this indication. (0.075% Axsain cream is NOT licensed for osteoarthritis)
07.04.02
Solifenacin
Overactive bladder (adults)
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Preferred
1st line unless contra-indicated
04.07.03
04.07.04
04.08.01
Gabapentin
Pain (Neuropathic)
Green
Formulations :
  • Capsules
  • Oral solution
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
CD
NICE
Important
First line gabapentinoid.
04.07.03
Duloxetine
Pain (Neuropathic)
Green
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
Important
Licensed only for diabetic peripheral neuropathic pain but also recommended as per NICE CG173 (off- label indication) as a treatment option in neuropathic pain.
04.07.03
04.07.04
Amitriptyline hydrochloride
Pain (Neuropathic)
Green
Formulations :
  • Oral solution
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Preferred
Ropinirole
Restless Leg Syndrome
Green
Formulations :
  • Immediate release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Preferred
Patients with severe symptoms, who are obese, co-morbid depression, increased risk of falls or cognitive impairment
10.02.02
Pridinol
Spasticity and muscle spasm
Green
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
U
09.06.04
Colecalciferol
Vitamin D deficiency and insufficiency
Green
Formulations :
  • Capsules
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
1,000iu tablets 50,000iu capsules
09.06.04
Vitamin D deficiency and insufficiency
Green (see narrative)
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
Important
4,000iu tablets reserved for patients unable to comply with weekly dosing
09.06.04
Vitamin D deficiency and insufficiency
Green (see narrative)
Formulations :
  • Oral solution
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
Important
50,000iu/ml oral solution in ampoules - reserved for patients unable to swallow tablets / capsules
09.06.04
Vitamin D deficiency and insufficiency
Green (see narrative)
Formulations :
  • Oral drops
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
Important
10,000iu/ml oral drops sugar free - reserved for patients unable to swallow tablets / capsules
04.07.03
Lidocaine
Post herpetic neuralgia
Green (see narrative)
Formulations :
  • Medicated plaster
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Post herpetic neuralgia only. Acute Trusts are restricted to Pain Team initiation only
04.07.03
04.07.04
04.08.01
Pregabalin
Pain (Neuropathic)
Green (see narrative)
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
SA
Important
Gabapentin is preferred due to lower potential for misuse. Pregabalin capsules more cost effective than tablets
04.07.03
04.07.04
04.08.01
Pain (Neuropathic)
Green (see narrative)
Formulations :
  • Oral solution
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
10.03.02
Capsaicin
Pain (Neuropathic)
Green (see narrative)
Formulations :
  • Cream
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Important
For patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine)
0.075% cream (Axsain brand) is licensed for this indication
04.07.02
Morphine sulfate
Pain
Green (see narrative)
Formulations :
  • Immediate release tablets
  • Oral solution
  • Oro-dispersible
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
Orodispersible tablets are a cost-effective alternative to oral solution. Reserve oral solution and orodispersible tablets for patients in whom a solid dose form is not suitable.
04.07.02
Pain
Green (see narrative)
Formulations :
  • Capsules (slow release)
  • Granules (slow release)
  • Tablets (slow release)
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
Prescribe modified-release preparations by brand - refer to local guidelines for preferred brands. Zomorph capsules (12-hourly) can be opened for administration in patients unable to swallow the capsules.
04.07.02
Tramadol hydrochloride
Pain (Neuropathic)
Green (see narrative)
Formulations :
  • Capsules
  • Soluble tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
Important
NICE CG 173 Consider tramadol only if acute rescue therapy is needed. Prescribe a short course (2-4 weeks on an acute script) and review at least every 3 months.
04.07.02
Pain (Neuropathic)
Green (see narrative)
Formulations :
  • Modified release capsules
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
Important
NICE CG 173 Consider tramadol only if acute rescue therapy is needed. Prescribe a short course (2-4 weeks on an acute script) and review at least every 3 months.
MR preparations to be prescribed by brand. Marol MR tablets are the locally preferred brand for primary care.
07.04.02
Solifenacin
Overactive bladder (adults)
Green (see narrative)
Formulations :
  • Oral suspension
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
Important
Only for patients with swallowing difficulties. Prescribe as solifenacin 1mg/ml oral SUSPENSION
06.06.02
Denosumab
Osteoporosis
Green (see narrative)
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
NICE
Important
Patients with a CKD of 4 or 5 and patients with a T-score of < -4.5 to remain under specialist care.
04.06.00
Domperidone
Nausea and vomiting (pregnancy)
Green (see narrative)
Formulations :
  • Oral suspension
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
SA
Un
Important
Safety alert and cardiac side-effects.
2nd line treatment option but should not be prescribed for longer than 7 days.
04.07.02
Oxycodone
Pain
Green (see narrative)
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
For use in patients where morphine sulfate is not suitable / not tolerated. Modified-release preparations to be prescribed by brand
04.07.02
Pain
Green (see narrative)
Formulations :
  • Capsules
  • Oral solution
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
For patients unable to tolerate / poor response to morphine. Modified-release preparations to be prescribed by brand
04.07.02
Tramadol hydrochloride
Pain
Green (see narrative)
Formulations :
  • Modified release capsules
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
SA
Important
Branded prescribing is recommended for modified release tramadol. Do not confuse 12 hourly and 24 hourly preparations. Consider tramadol where maximum tolerated doses of codeine / dihydrocodeine are ineffective.
04.07.02
Pain
Green (see narrative)
Formulations :
  • Soluble tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
Reserved for patients unable to swallow solid dose forms or for administration via an enteral tube. Consider use where maximum tolerated doses of codeine / dihydrocodeine are ineffective.
04.07.02
Pain
Green (see narrative)
Formulations :
  • Oro-dispersible
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
Reserved for patients unable to swallow solid dose forms or for administration via an enteral tube. Consider use where maximum tolerated doses of codeine / dihydrocodeine are ineffective.
04.07.02
Pain
Green (see narrative)
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
Consider use where maximum tolerated doses of codeine / dihydrocodeine are ineffective.
04.07.04
04.08.01
Topiramate
Migraine (prevention)
Green (see narrative)
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
SA
Important
Pregnancy Prevention Plan required for females of childbearing potential.
Capsules (Sprinkle) reserved for use in patients who cannot swallow tablets.
04.07.04
04.08.01
Migraine (prevention)
Green (see narrative)
Formulations :
  • Oral suspension
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
SA
Important
Pregnancy Prevention Plan required for females of childbearing potential.
Only use where patient cannot swallow tablets or capsules (sprinkle) are not suitable.
07.04.01
Terazosin hydrochloride
Benign prostatic hyperplasia
Green (see narrative)
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
R
Important
Restricted for patients with renal or hepatic failure
07.04.01
Alfuzosin hydrochloride
Benign prostatic hyperplasia
Green (see narrative)
Formulations :
  • Modified release tablets
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
2nd or 3rd line. Tamsulosin MR capsules or Doxazosin immediate release tablets are preferred
01.03.05
Omeprazole
Acid Suppression (Children)
Green (see narrative)
Formulations :
  • Dispersible tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
01.03.05
Acid Suppression (Children)
Green (see narrative)
Formulations :
  • Dispersible tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Mezzopram is the preferred brand - smaller granule size. Omeprazole MUPS is an alternative. Disperse in water then mix with juice, apple sauce or yoghurt
01.07.04
Glyceryl trinitrate
Anal fissures
Green (see narrative)
Formulations :
  • Ointment
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Preferred
0.4% ointment is the 1st-line treatment option in adults
01.03.05
Pantoprazole
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
2nd line in adults without swallowing difficulties. (Suitable for patients that cannot have animal-derived products / capsules.)
01.03.05
Rabeprazole sodium
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
2nd line in adults without swallowing difficulties. (Suitable for patients that cannot have animal-derived products / capsules.)
01.03.05
Esomeprazole
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Lansoprazole capsules are the preferred option. Esomeprazole 40mg restricted to short-term use or for Zollinger-Ellison syndrome.
01.03.05
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Granules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
3rd-line. Restricted to patients with swallowing difficulties or with large bore enteral feeding tube when other options are not clinically appropriate. Do not use in tubes less than 6F.
01.03.05
Lansoprazole
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Oro-dispersible
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
1st line in adults with swallowing difficulties. 1st line for patients with enteral feeding tubes.
01.03.05
Omeprazole
Acid Suppression (Children)
Blue
Formulations :
  • Oral suspension
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
01.03.05
Acid Suppression (Children)
Blue
Formulations :
  • Oral suspension
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
R
Important
Only for children under 10kg and/or with a feeding tube less than 8Fr
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Ciclosporin
Dry eyes
Blue
Formulations :
  • Eye drops (unit dose)
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
NICE
Important
0.1% ciclosporin (Ikervis)
Testosterone (gel)
Low sexual desire in menopausal women
Blue
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Low sexual desire in menopausal women
Blue
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
06.01.02
Dapagliflozin
Heart failure
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
NICE
06.01.02
Empagliflozin
Heart failure
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
NICE
Daridorexant
Insomnia in adults
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
01.05.02
06.03.02
Budesonide
Oesophagitis (maintenance)
Blue
Formulations :
  • Oro-dispersible
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
04.07.02
Tapentadol hydrochloride
Pain (non-malignant)
Blue
Formulations :
  • Modified release tablets
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
R
Important
Only on recommendation by a pain specialist for patients not responding to / not tolerating morphine or oxycodone
04.09.01
Co-beneldopa
Parkinson's disease
Blue
Formulations :
  • Capsules
  • Capsules (slow release)
  • Dispersible tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
04.09.01
Entacapone
Parkinson's disease
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Important
Preferred
Preferred COMT inhibitor
04.08.01
04.08.02
Clonazepam
Parkinson's disease
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
Important
Rapid eye movement disorder
04.02.01
Quetiapine
Parkinson's Disease (psychosis)
Blue
Formulations :
  • Modified release tablets
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
Sildenafil
Penile rehabilitation
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
04.09.01
Pramipexole
Parkinson's disease
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
04.09.01
Parkinson's disease
Blue
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
04.09.01
Rasagiline mesilate
Parkinson's disease
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
04.09.01
Selegiline hydrochloride
Parkinson's disease
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
04.09.01
Ropinirole hydrochloride
Parkinson's disease
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
04.09.01
Parkinson's disease
Blue
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
04.09.01
Rotigotine
Parkinson's disease
Blue
Formulations :
  • Patches
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Important
Consider patches if levodopa and / or oral dopamine are not effective in treating nocturnal akinesia
04.01.01
Melatonin
Parkinson's disease
Blue
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
Important
Rapid eye movement disorder.
Generic 2mg MR tablets.
FreeStyle Libre 2 (Intermittently scanned continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Blue
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Dexcom ONE (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Blue
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
04.08.01
10.02.02
Cannabis (medicinal)
Spasticity and muscle spasm
Blue
Formulations :
  • Oromucosal spray
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
Important
For spasticity in MS. Specialist to prescribe for the first 12 weeks and determine response before transfer of care.
10.01.03
Leflunomide
Respiratory disease indications
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
06.07.02
Nafarelin acetate
Transgender Health - Children & Young People
Amber
Formulations :
  • Nasal spray
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.07.02
08.03.04
Leuprorelin acetate
Transgender Health - Children & Young People
Amber
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.07.02
Goserelin acetate
Transgender Health - Children & Young People
Amber
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.04.02
Cyproterone acetate
Transgender Health - adults
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.04.02
Finasteride
Transgender Health - adults
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.04.01
07.02.01
Estradiol
Transgender Health - adults
Amber
Formulations :
  • Gel
  • Patches
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.04.01
Ethinylestradiol
Transgender Health - adults
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.07.02
Goserelin acetate
Transgender Health - adults
Amber
Formulations :
  • Implant
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.04.01
Medroxyprogesterone acetate
Transgender Health - adults
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.07.02
08.03.04
Leuprorelin acetate
Transgender Health - adults
Amber
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.04.02
Testosterone
Transgender Health - adults
Amber
Formulations :
  • Gel
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.07.02
Triptorelin
Transgender Health - adults
Amber
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
10.01.03
Leflunomide
Rheumatology indications
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
04.08.01
Sodium valproate (with childbearing potential)
Epilepsy
Amber
Formulations :
  • Capsules (slow release)
  • Granules (slow release)
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
SA
Important
Pregnancy Prevention Programme required. See MHRA advice
04.08.01
Epilepsy
Amber
Formulations :
  • Gastro-resistant tablets
  • Modified release tablets
  • Oral solution
  • Tablets
  • Crushable tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
SA
Important
Pregnancy Prevention Programme required. See MHRA advice
04.04.00
Guanfacine
Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Amber
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
04.04.00
Methylphenidate hydrochloride
Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Amber
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
Important
Prescribe by brand. Xaggitin XL, Xenidate XL and Delomsart are the locally agreed brands.
04.04.00
Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Amber
Formulations :
  • Immediate release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
Important
Prescribe immediate release tablets generically
10.01.03
13.05.03
Baricitinib
Atopic dermatitis
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
SA
ICB
BlueTeq
NICE
13.05.03
Tralokinumab
Atopic dermatitis
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
SA
ICB
BlueTeq
NICE
01.05.03
10.01.03
13.05.03
Upadacitinib
Atopic dermatitis
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
SA
ICB
BlueTeq
NICE
Continuous Glucose Monitoring
Congenital hyperinsulinism
Red
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
ICB
BlueTeq
Sotrovimab
Covid-19
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Remdesivir
Covid-19
Red
Formulations :
  • Intravenous infusion
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
01.03.05
Omeprazole
Acid Suppression (Children)
Red
Formulations :
  • Powder
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
R
U
Important
Aclomep powder - ASPH NICU only
01.03.03
Sucralfate
Gastro protection
Red
Formulations :
  • Oral suspension
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
U
01.05.03
10.01.03
13.05.02
13.05.03
Risankizumab
Crohn's disease
Red
Formulations :
  • Intravenous injection (IV)
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
04.08.01
Cenobamate
Epilepsy
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
For initiation by tertiary centres only
04.08.01
Sodium valproate (with childbearing potential)
Epilepsy
Red
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
SA
Important
Pregnancy Prevention Programme required. See MHRA advice
Insulin pump - Type 1 diabetes
Diabetes Mellitus
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
11.04.01
Dexamethasone
Diabetic macular oedema
Red
Formulations :
  • Intravitreal implant
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ophthalmology specialists only
04.07.04
Rimegepant
Migraine (prevention)
Red
Formulations :
  • Oral lyophilisates
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
For episodic migraine only
04.07.04
Erenumab
Migraine (prevention)
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Preferred
04.07.04
Fremanezumab
Migraine (prevention)
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
Sarilumab
Rheumatoid arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Severe disease only
01.05.03
10.01.03
Tofacitinib
Rheumatoid arthritis
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
SA
ICB
BlueTeq
NICE
Important
Severe disease only
11.04.01
Loteprednol etabonate
Post-op ocular inflammation
Red
Formulations :
  • Eye drops
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Bimekizumab
Psoriasis
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Deucravacitinib
Psoriasis
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
SA
ICB
BlueTeq
NICE
13.05.02
13.05.03
Tildrakizumab
Psoriasis
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
Ustekinumab
Psoriatic arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
01.05.03
10.01.03
13.05.02
13.05.03
Risankizumab
Psoriatic arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
04.07.02
Morphine sulfate
Pain
Red
Formulations :
  • Injection
  • Solution for infusion
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
See separate listing for palliative care
04.02.01
Clozapine
Parkinson's Disease (psychosis)
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
SA
NICE
Important
Patient monitoring and registration required
06.07.01
Bromocriptine
Parkinson's disease
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
SA
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
04.09.01
Cabergoline
Parkinson's disease
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
04.06.00
Domperidone
Parkinson's Disease (apomorphine pre-treatment)
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
04.09.01
Pergolide mesilate
Parkinson's disease
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
04.07.02
Tramadol hydrochloride
Pain
Red
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
04.06.00
Domperidone
Lactation stimulation
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
SA
Un
01.09.01
Chenodeoxycholic acid
Metabolic disorders
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NHSE
10.02.02
Mexiletine hydrochloride
Myotonia
Red
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NHSE
BlueTeq
NICE
04.07.02
Oxycodone
Pain
Red
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
Alternative for patients unable to tolerate / poor response to morphine. Care with dose conversion.
09.06.04
Colecalciferol
Vitamin D deficiency and insufficiency
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
Important
25,000iu tablets
06.01.02
Liraglutide
Weight management in adults
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
06.01.02
Semaglutide
Weight management in adults
Red
Formulations :
  • Pre-filled pen
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
R
NICE
06.02.01
Liothyronine sodium
Treatment resistant depression
Red
Formulations :
  • Capsules
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
R
Un
Important
Consultant psychiatrists only.
FreeStyle Libre 3 (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Red
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
Dexcom G7 (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Red
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
Oscillating Positive Expiratory Pressure Device
Mucous clearance
N/A
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
04.07.03
04.07.04
04.08.01
Gabapentin
Migraine (prevention)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
NFD1
NICE
04.07.03
04.07.04
04.08.01
Pregabalin
Migraine (prevention)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
NFD1
04.01.01
Melatonin
Jet lag disorder
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
01.05.02
Prednisolone
Inflammatory bowel disease
Non Formulary
Formulations :
  • Foam enema
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
Important
Budesonide rectal foam is preferred. Steroid safety considerations
06.04.02
Testosterone
Low sexual desire in menopausal women
Non Formulary
Formulations :
  • Cream
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
U
Important
Androfeme is unlicensed in the UK. Other products can be used off-label
07.04.02
Tamsulosin hydrochloride
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
Important
Use modified release capsules
07.04.01
07.04.05
Vardenafil
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
07.04.01
Doxazosin
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
Important
Use immediate release tablets
07.04.01
07.04.05
Avanafil
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
01.03.05
Omeprazole
Acid Suppression (Children)
Non Formulary
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
01.07.04
Glyceryl trinitrate
Anal fissures
Non Formulary
Formulations :
  • Ointment
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
U
Important
0.4% ointment is the 1st-line treatment option in adults. 0.1%, 0.2% and 2% ointments are non-formulary
01.03.05
Lansoprazole
Acid suppression (Adults)
Non Formulary
Formulations :
  • Liquid
  • Oral solution
  • Oral suspension
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Lansoprazole oro-dispersible tablets are 1st-line for adults with swallowing dificulties or enteral feeding tubes.
01.03.05
Esomeprazole
Acid suppression (Adults)
Non Formulary
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
01.03.05
Omeprazole
Acid suppression (Adults)
Non Formulary
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
Important
Omeprazole or lansoprazole capsules are 1st-line. Pantoprazole or rabeprazole tablets are 2nd-line for patients without swallowing difficulties (suitable for patients that cannot have animal-derived products).
01.03.05
Acid suppression (Adults)
Non Formulary
Formulations :
  • Oral suspension
  • Oro-dispersible
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
Important
Omeprasole capsules can be opened for patients with swallowig difficulties. Lansoprazole oro-dispersible tablets are 1st-line for patients with enteral feeding tubes
07.04.01
Indoramin
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
07.04.01
Prazosin hydrochloride
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
07.04.01
Sildenafil
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.07.02
Morphine sulfate
Pain
Non Formulary
Formulations :
  • Suppositories
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
04.07.02
Tramadol with Dexketoprofen
Pain
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
04.07.02
Tramadol hydrochloride
Pain
Non Formulary
Formulations :
  • Oral solution
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
04.07.02
Pain
Non Formulary
Formulations :
  • Oral drops
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
04.07.03
07.04.02
Imipramine hydrochloride
Overactive bladder (adults)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
07.04.02
Solifenacin
Overactive bladder (adults)
Non Formulary
Formulations :
  • Oral solution
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
NFD1
Important
Prescribe as solifenacin 1mg/ml oral SUSPENSION
04.07.03
Nortriptyline
Pain (Neuropathic)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
10.03.02
Capsaicin
Pain (Neuropathic)
Non Formulary
Formulations :
  • Patches
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
Important
For patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine)
04.09.02
Trihexyphenidyl hydrochloride
Parkinson's disease
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.01
Co-beneldopa
Parkinson's disease (challenge test)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.01
Co-careldopa
Parkinson's disease (challenge test)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.01
Apomorphine hydrochloride
Parkinson's disease (challenge test)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.01
Ropinirole hydrochloride
Parkinson's disease (neuroprotective therapy)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.01
Selegiline hydrochloride
Parkinson's disease (neuroprotective therapy)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.01
Rasagiline
Parkinson's disease (neuroprotective therapy)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.01
Pramipexole
Parkinson's disease (neuroprotective therapy)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.02
Orphenadrine hydrochloride
Parkinson's disease
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.02
Procyclidine hydrochloride
Parkinson's disease
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.02.01
Olanzapine
Parkinson's Disease (psychosis)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
07.04.01
07.04.05
Vardenafil
Penile rehabilitation
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
03.04.01
Alimemazine tartrate
Sleep disorders in children and adolescents
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
Un
GlucoRx Aidex (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Non Formulary
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Glucomen Day (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Non Formulary
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
A8 Touchcare Nano (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Non Formulary
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Dexcom G6 (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Non Formulary
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Medtronic Guardian (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Non Formulary
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
04.06.00
Betahistine hydrochloride
Tinnitus
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
HRT continuous combined
Menopausal disorders
See Below
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Molnupiravir
Covid-19
See narrative
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Covid-19
See narrative
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
06.04.01
07.02.01
Estradiol
Transgender Health - Children & Young People
See narrative
Formulations :
  • Patches
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.04.02
Testosterone
Transgender Health - Children & Young People
See narrative
Formulations :
  • Gel
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.07.02
Triptorelin
Transgender Health - Children & Young People
See narrative
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More